BCAB Logo

BioAtla, Inc. (BCAB) 

NASDAQ
Market Cap
$99.09M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
202 of 776
Rank in Industry
117 of 433

Largest Insider Buys in Sector

BCAB Stock Price History Chart

BCAB Stock Performance

About BioAtla, Inc.

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen …

Insider Activity of BioAtla, Inc.

Over the last 12 months, insiders at BioAtla, Inc. have bought $172,540 and sold $0 worth of BioAtla, Inc. stock.

On average, over the past 5 years, insiders at BioAtla, Inc. have bought $19.88M and sold $50.54M worth of stock each year.

Highest buying activity among insiders over the last 12 months: STEINMAN LAWRENCE (director) — $123,144. SHORT JAY M PHD (Chief Executive Officer) — $106,910. Vasquez Christian (See Remarks) — $15,262.

The last purchase of 4,000 shares for transaction amount of $9,320 was made by MCBRINN SYLVIA (director) on 2023‑12‑26.

List of Insider Buy and Sell Transactions, BioAtla, Inc.

2023-12-26Purchasedirector
4,000
0.0082%
$2.33$9,320-9.66%
2023-12-20PurchaseChief Executive Officer
50,000
0.1107%
$2.14$106,910+6.14%
2023-12-19PurchaseSee Remarks
7,495
0.0159%
$2.04$15,262+7.29%
2023-12-19Purchasedirector
20,000
0.0427%
$2.05$41,048+7.29%
2023-09-08Purchasedirector
2,000
0.0044%
$2.54$5,080-17.05%
2023-03-29PurchaseChief Executive Officer
40,800
0.0845%
$2.47$100,862+1.79%
2023-03-28PurchaseSee Remarks
20,000
0.0429%
$2.40$47,970+8.51%
2023-03-28Purchasedirector
4,000
0.0084%
$2.35$9,400+8.51%
2022-12-19Purchasedirector
3,700
0.0097%
$8.33$30,813-64.47%
2022-11-22Purchasedirector
2,000
0.0048%
$8.27$16,540-66.02%
2022-08-12PurchaseChief Executive Officer
26,350
0.0788%
$7.84$206,600-46.78%
2022-06-21PurchaseChief Executive Officer
40,308
0.114%
$2.91$117,296+40.73%
2022-06-07PurchaseSee Remarks
10,000
0.0258%
$2.97$29,720+25.65%
2021-12-02SaleChief Executive Officer
4,811
0.0135%
$21.76$104,666-70.68%
2021-12-02SalePresident
2,984
0.0084%
$21.76$64,918-70.68%
2021-12-02SaleChief Financial Officer
1,434
0.004%
$21.76$31,198-70.68%
2021-12-02SaleChief Medical Officer
820
0.0023%
$21.76$17,839-70.68%
2021-12-02SaleSee Remarks
200
0.0006%
$21.76$4,351-70.68%
2021-12-01SaleChief Executive Officer
24,321
0.0763%
$23.03$560,226-69.08%
2021-12-01SalePresident
628
0.002%
$23.03$14,466-69.08%

Insider Historical Profitability

<0.0001%
SHORT JAY M PHDChief Executive Officer
1439283
2.9777%
$2.05413<0.0001%
Vasquez ChristianSee Remarks
115659
0.2393%
$2.0537+17.08%
STEINMAN LAWRENCEdirector
38459
0.0796%
$2.0514
MCBRINN SYLVIAdirector
15125
0.0313%
$2.0550<0.0001%
Cormorant Asset Management, LP
2292060
4.742%
$2.0510+17.46%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Soleus Capital Management, L.P.$13.98M8.454.07M0%+$00.06
BlackRock$9.56M5.782.78M-3.62%-$358,836.70<0.0001
The Vanguard Group$7.22M4.362.1M+0.85%+$60,774.48<0.0001
Morgan Stanley$6.57M3.971.91M-0.15%-$10,220.24<0.0001
Tang Capital Management, LLC$5.07M3.061.47M-41.6%-$3.61M0.02
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.